Bionexus Gene LabBGLC
13F holders, Q2 2026 (June 30)3holders +1
2new positions
1sold out
$1.89avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding Bionexus Gene Lab Corp. (BGLC) in their 13F filings, up 1 from Q1 2026. 2 opened new positions and 1 sold out. The largest holders were HRT Financial LP ($27K), UBS Group AG ($197) and Caitong International Asset Management Co., Ltd ($2).
- Company
- Bionexus Gene Lab Corp.
- CUSIP
- 090628306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $27K |
| Exits | 1 | $2 |
All 13F filers, Q1 2026 → Q2 2026: 14,284 shares bought and 131 shares sold, net +14,153 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| HRT Financial LP | 0.00% | New | 14,283 | $27K |
| UBS Group AG | 0.00% | Reduce -56.3% | 101 | $197 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is BGLC's weight in each manager's 13F, not the share of Bionexus Gene Lab Corp. the manager owns.